TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00841256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
Study: NCT04371978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 MG
Description: Linagliptin 5 mg PO once daily
Study: NCT01479881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
Study: NCT03892759

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic Manipulative Therapy
Description: A set of hands-on techniques used by Osteopathic Physicians for the assessment and treatment of somatic dysfunction.
Study: NCT01573091

Intervention type: PROCEDURE
Intervention: Cardiac Resynchronization Therapy
Description: Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
Study: NCT00949130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL103
Description: BID for 7-14 days
Study: NCT01740908

Intervention type: OTHER
Intervention: Hyperbaric Oxygen Treatment
Description: Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.~All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days.
Study: NCT03956680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986301
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986301
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986301
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986301
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986301
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT03424005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib tablets will be administered by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib tablets will be administered by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib tablets will be administered by mouth once daily.
Study: NCT00949130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: BID for 7-14 days
Study: NCT03956680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT03424005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib tablets will be administered by mouth once daily.
Study: NCT04195698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib will be administered oral as tablet
Study: NCT03025256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture for cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI of brain and spine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV or IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT03956680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT02764957

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green coffee extract
Study: NCT01320930

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: conventional care
Study: NCT01521884

Intervention type: OTHER
Intervention: SC anti-TNF
Description: SC anti-TNF
Study: NCT02764957

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00004465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNSORB Pk
Study: NCT02505100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touching relaxant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnoses
Study: NCT04559256

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Patients will receive a cardiopulmonary exercise testing before and 3-month after tricuspid intervention
Study: NCT03422926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social marketing campaign
Description: Messaging campaign designed to help mothers in choosing healthful options when dining out.
Study: NCT04001608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seraprevir
Description: Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
Study: NCT02318121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy first
Description: rupture of membranes to augment labor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin first
Description: Administration of oxytocin to augment labor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy and oxytocin
Description: Rupture of membranes and administration of oxytocin to augment labor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT01689259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL TNX-102 at 2.4 mg
Description: 1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL TNX-102 at 4.8 mg
Description: 2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL TNX-102-A at 2.4 mg
Description: 1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine tablets
Description: 1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
Study: NCT00981604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILS
Description: Single Incision Laparoscopic Cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscopic Cholecystectomy
Description: 4 port technique
Study: NCT00858000

Intervention type: OTHER
Intervention: Retrospective analysis of already archived samples
Description: RNA extracted from tissue samples already archived
Study: NCT00319956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
Study: NCT00004465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00319956

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
Study: NCT03199807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NRT
Description: Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory. NRTs 0.5\~1 x 10\^10, will be i.v.Q3 weeks for total 4-6 doses.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of the major mass by dose of 5Gy/F \* 10F
Study: NCT02938793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: intravenous administration
Study: NCT03953053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser Assissted Cataract Surgery
Description: During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Laser Assissted Cataract Surgery
Description: During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body
Study: NCT00784303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib (DTC Cohort)
Description: 24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib (MTC Cohort)
Description: 24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.
Study: NCT04376944

Intervention type: OTHER
Intervention: Survey
Description: questionnaire on their symptoms and their exposures

Intervention type: OTHER
Intervention: Survey
Description: questionnaire on their symptoms and their exposures
Study: NCT02255305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Patients in the FMT group will receive \~50 grams of fecal material suspended in bacteriostatic normal saline and glycerol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobials
Description: Patients randomized to the control group will receive antimicrobials targeting C. difficile.
Study: NCT01167881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Medium dose once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1-4 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching Glimepiride
Study: NCT00537316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Description: IFX intravenous (IV) infusion dosed at 5mg/kg of body weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Description: IFX intravenous (IV) infusion dosed at 5mg/kg of body weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Description: IFX intravenous (IV) infusion dosed at 5mg/kg of body weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Description: IFX intravenous (IV) infusion dosed at 5mg/kg of body weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Description: IFX intravenous (IV) infusion dosed at 5mg/kg of body weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Description: IFX intravenous (IV) infusion dosed at 5mg/kg of body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine (AZA)
Description: AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Description: AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Description: AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Description: AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
Study: NCT02178709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle.
Study: NCT04593290

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oticon Opn S 1 miniRITE hearing aid
Description: Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oticon Opn S 1 miniRITE hearing aid
Description: Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.
Study: NCT00537316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Azathioprine
Description: Placebo to AZA tablet orally every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Placebo to IFX intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo infusion
Description: Placebo to IFX intravenous (IV) infusion
Study: NCT02709356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1-month of 60-40 MCT oil
Description: 1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1-month of 60-40 MCT oil
Description: 1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
Study: NCT00537316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo infusion
Description: Placebo to IFX intravenous (IV) infusion
Study: NCT05113979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuraSee IOPCL with +3.0D add
Description: The IOPCL (intraocular pseudophakic contact lens) consists of a 4.5mm diameter optic. All subjects will receive a +3.0 power regardless of diopter power based on IOL Master. This IOPCL will be coupled to a Bausch and Lomb Model LI61SE or LI61AO intraocular lens to correct residual refractive errors after cataract surgery.
Study: NCT01727544

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cartilage cap occlusion surgery
Description: placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
Study: NCT00421018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single corticosteroid inhalers and Singulair
Description: Treatment steps according to preset algorithm

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Single corticosteroid inhalers and Singulair
Description: Treatment steps according to preset algorithm
Study: NCT02671084

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane
Description: compare effect of sevoflurane when administered before PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: compare effect of sevoflurane when administered before PCI
Study: NCT02776891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium citrate
Description: Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and standardized uptake value (SUV) calculation.
Study: NCT02709356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1-month of C8 MCT oil
Description: 1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1-month of C8 MCT oil
Description: 1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)
Study: NCT01328145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: 500 mg /day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid
Description: 500 mg /day
Study: NCT01657539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt containing probiotics
Description: patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt
Description: Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
Study: NCT02370628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Description: The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~* Step 1: facet block~* Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Facet block
Description: A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty.
Study: NCT04459481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bending angle
Description: patients in 70-degree bending angle group are intubated with video stylet at 70-degree bending angle patients in 90-degree bending angle group are intubated with video stylet at 90-degree bending angle
Study: NCT02370628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facet block
Description: A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty.
Study: NCT04793009

Intervention type: DEVICE
Intervention: funnel-shaped, intraperitoneal mesh placement
Description: Implantation of a prophylactic, 3D funnel-shaped, intraperitoneal, non-absorbable and synthetic mesh (Dyna Mesh IPST 2x15x15 cm™ and 3x16x16 cm™, FEG Textiltechnik, Aachen, Germany,)
Study: NCT00068367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150 mg per day, daily until disease progression